Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17195015 | 0.84 | CXCR3 (0.30) | — | |
| SCHEMBL10080745 | 0.81 | SRC (0.31) | — | |
| SCHEMBL23115077 | 0.79 | — | — | |
| SCHEMBL2185976 | 0.79 | CXCR3 (0.30) | — | |
| SCHEMBL28824664 | 0.79 | — | — | |
| SCHEMBL13412816 | 0.78 | ADORA2A (0.32) | — | |
| SCHEMBL15158946 | 0.77 | POLB (0.38) | ACHEPOLBTOP2A | |
| SCHEMBL10308906 | 0.76 | ATM (0.32) | — | |
| SCHEMBL17195013 | 0.76 | — | — | |
| SCHEMBL7816611 | 0.75 | HDAC1 (0.41) | ACHEPOLBTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | ACHE 3589/4885POLB 2641/4885TOP2A 3200/4885 |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | ACHE 4843/4885POLB 3787/4885TOP2A 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.